How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,463 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value

to thank Erin Lawler, Molly Morgan, and Aqsa Mugal for their contributions to this report.©Institute for Clinical and Economic Review, 2018 Page ii Evidence Report – CAR-T Therapies for B-Cell Cancers About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work (...) be assumed to support any part of this report, which is solely the work of the ICER team and its affiliated researchers. For a complete list of stakeholders from whom we requested input, please visit: https://icer-review.org/topic/car-t/. Expert Reviewers Charalambos (Babis) Andreadis, MD, MCSE Associate Professor of Clinical Medicine, Department of Medicine; Director, Clinical Research Support Office University of California, San Francisco (UCSF) Medical Center and UCSF Helen Diller Family Comprehensive

2018 California Technology Assessment Forum

62. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy Full Text available with Trip Pro

and electrolyte balance, minimizing insensible water losses, and preventing infection. Given the immune mechanism of action of these medicines, use of immune suppression, such as with systemic corticosteroids, is warranted and should be offered, though the use of systemic corticosteroids has been more controversial for the treatment of SJS/TEN, in general. For DRESS/DIHS, high-dose and usually prolonged courses of systemic corticosteroids is first-line therapy following cessation of the offending drug (...) of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA. Abstract Section: Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology

2018 American Society of Clinical Oncology Guidelines

63. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer

in patients with early-stage, HER2-positive breast cancer. Neratinib causes substantial diarrhea, and diarrhea prophylaxis must be used. Additional information can be found at . INTRODUCTION Section: In 2016, ASCO published an adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)–positive breast cancers. ASCO updates its guidelines at intervals (...) breast cancer? Should neratinib be offered as extended adjuvant therapy for patients after combination chemotherapy and trastuzumab-based adjuvant therapy with early-stage, HER2-positive breast cancer? Target Population Patients who are being considered for, or who are receiving, systemic therapy following definitive surgery for early-stage invasive breast cancer, defined largely as invasive cancer anatomic stages I to IIIC Target Audience Medical oncologists, pathologists, surgeons, oncology nurses

2018 American Society of Clinical Oncology Guidelines

64. Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Academy of Neurology AEs: adverse effects ALT: alanine aminotransferase ARRs: annualized relapse rates AST: aspartate aminotransferase CIS: clinically isolated syndrome CMSC: Consortium of Multiple Sclerosis Centers” COI: conflict of interest CV: curriculum vitae DMTs: disease-modifying therapies EDSS: Expanded Disability Status Scale FDA: US Food and Drug Administration GDDI: Guideline Development, Dissemination, and Implementation Subcommittee IOM: Institute of Medicine mIUs: milli-international (...) by the GDDI before and after the public comment period. Panel members developed the clinical questions and the data extraction template. The guideline panel defined DMTs as medications that aim to affect the clinical course of MS by decreasing relapses or slowing disease progression or both. The guideline panelists limited the search for relevant literature to medications that have been approved by the US Food and Drug Administration (FDA), Health Canada, or the European Medicines Agency

2018 American Academy of Neurology

65. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value

to thank Erin Lawler, Molly Morgan, and Aqsa Mugal for their contributions to this report.©Institute for Clinical and Economic Review, 2018 Page ii Final Evidence Report – CAR-T Therapies for B-Cell Cancers About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its (...) or should be assumed to support any part of this report, which is solely the work of the ICER team and its affiliated researchers. For a complete list of stakeholders from whom we requested input, please visit: https://icer-review.org/topic/car-t/. Expert Reviewers Charalambos (Babis) Andreadis, MD, MCSE Associate Professor of Clinical Medicine, Department of Medicine; Director, Clinical Research Support Office University of California, San Francisco (UCSF) Medical Center and UCSF Helen Diller Family

2018 California Technology Assessment Forum

66. Migraine: Drugs for the prevention of migraine

disorders. Respiratory disorders — cough, and dyspnoea. Gastrointestinal disorders — gastrointestinal discomfort, constipation, diarrhoea, vomiting, dry mouth, nausea, anorexia and altered taste. Renal disorders — nephrolithiasis. Skin disorders — alopecia, decreased sweating, pruritus, and rash. Eye disorders — topiramate has been associated with acute myopia with secondary angle closure glaucoma and uveitis. Metabolic disorders — metabolic acidosis. Hyperammonemia with or without encephalopathy has (...) Migraine: Drugs for the prevention of migraine Drugs for the prevention of migraine | Prescribing information | Migraine | CKS | NICE Search CKS… Menu Drugs for the prevention of migraine Migraine: Drugs for the prevention of migraine Last revised in April 2019 Drugs for the prevention of migraine Propranolol Cautions and contraindications Do not prescribe propranolol to people with: Asthma or obstructive airways disease — may precipitate bronchospasm that is unresponsive to beta2-agonists

2018 NICE Clinical Knowledge Summaries

67. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial Full Text available with Trip Pro

Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature, sequence, and clinical content: . National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Save citation to file Format: Create

2020 EvidenceUpdates

68. Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

in the neratinib group compared to the placebo group (70 vs. 109 events). The two-year invasive DFS rate was 93.9% (95% CI 92.4–95.2) and 91.6% (95% CI 90.0–93.0) in the neratinib and placebo groups, respectively. At the time of primary analysis the secondary outcome, overall survival (OS), was immature, since the target number of OS events had not been reached. The most common treatment-emergent adverse event (AE) in the neratinib group was diarrhoea: Over 90% of the patients had diarrhoea of any grade (40 (...) Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66. Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy - Repository of AIHTA GmbH English | Browse - - - Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment

2017 Austrian Institute of Health Technology Assessment

69. Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea

a concomitant infection. Patients receiving treatment with an anti-diarrheal drug in the five days prior to the study were also excluded. Pregnant or lactating women and women planning pregnancy were also ineligible for study participation. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its (...) Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2015 Clinical Trials

70. Efficacy of Chinese patent medicine in providing relief of diarrhea-predominant irritable bowel syndrome: a literature review of randomized trials

Efficacy of Chinese patent medicine in providing relief of diarrhea-predominant irritable bowel syndrome: a literature review of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors

2018 PROSPERO

71. Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines

(PPIs), contact with possibly infected persons, use of laxatives and other over-the-counter medications] and previous admission for diarrhoea. Earlier history of gastrointestinal diseases [e.g. in?am- matory bowel disease (IBD)] should also be assessed before the ini- tiation of antineoplastic therapy. Patients should be asked about incontinence as a factor included in the grading, as they may be reluctant to volunteer the information. Fever should be assessed, and temperature meas- ured. Other (...) therapies Classofdrug Drug Incidenceof diarrhoea(%) Incidenceof grade3and 4diarrhoea(%) Anti-EGFR Ge?nitib 26–52 1–5 Erlotinib 18–57 3–6 Afatinib 87–95 14–22 Cetuximab 13–28 4–28 Panitumumab 21 8–20 Anti-HER2 Lapatinib 47–75 3–14 Trastuzumab 2–63 2–6 Pertuzumab 67 5–8 Anti-BRAF Vemurafenib 5–6 0 Dabrafenib 1 0 Anti-MEK Cobimetinib 45–50 4 Trametinib 45–50 4 Anti-EML4/ALK Crizotinib 50–60 0 Anti-VEGF Bevacizumab 20 2–7 A?ibercept 58–69 13–19 Multi-targeted TKI Imatinib 20–26 1 Pazopanib 52 4 Sunitinib 44

2018 European Society for Medical Oncology

72. Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea Full Text available with Trip Pro

at Home and to Animals in Public Settings: Risks to Children Pickering et al [51] Review of Institute of Medicine and National Research Council Recommendations for One Health Initiative Rubin et al [208] Mode Title URL Author/Issuing Agency International travel Expert Review of the Evidence Base for Prevention of Travelers’ Diarrhea DuPont et al [113] Medical Considerations Before International Travel Freedman et al [207] The Yellow Book CDC Travelers Health CDC Immunocompromised hosts Guidelines (...) etiology. b. Ill immunocompetent people with fever documented in a medical setting, abdominal pain, bloody diarrhea, and bacillary dysentery (frequent scant bloody stools, fever, abdominal cramps, tenesmus) presumptively due to Shigella . c. People who have recently travelled internationally with body temperatures ≥38.5°C and/or signs of sepsis (weak, low). See . 31. The empiric antimicrobial therapy in adults should be either a fluoroquinolone such as ciprofloxacin, or azithromycin, depending

2017 Infectious Diseases Society of America

73. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

not so identified.xiii Definition of key terms Serodiscordant couples are couples in which one partner is living with HIV and the other is HIV-negative. A couple refers to two people in an ongoing sexual relationship; each of these people is referred to as a partner in the relationship. How individuals define their relationships will vary according to their cultural and social context. Antiretroviral therapy ARV (antiretroviral) drugs refer to the medicines used to treat HIV. ART (antiretroviral (...) ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTIONCONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION 2016 RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SECOND EDITIONWHO Library Cataloguing-in-Publication Data Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – 2nd ed. 1.HIV Infections – drug therapy. 2.HIV Infections – prevention

2016 World Health Organisation HIV Guidelines

74. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. From 1 Professor and Chair, Department of Nutrition Sciences, University of Alabama at Birmingham, Director, UAB Diabetes Research Center, GRECC Investigator & Staff Physician, Birmingham VA Medical Center, Birmingham, Alabama; 2 Director, Metabolic Support, Clinical Professor of Medicine, Division (...) School of Medicine, Internal Medicine, Endocrinology, Pediatrics, Pediatric Endocrinology, New Haven, Connecticut; 7 Walter Reed National Military Medical Center, Diabetes Obesity & Metabolic Institute, Bethesda, Maryland; 8 Assistant Clinical Professor, Mount Sinai School of Medicine, NY, ProHealth Care Associates, Division of Endocrinology, Lake Success, New York; 9 Center for Weight Management, Division of Endocrinology, Diabetes and Metabolism, Scripps Clinic, San Diego, California. Address

2016 American Association of Clinical Endocrinologists

75. Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.

in the prevention of antibiotic induced diarrhea and Clostridium difficile diarrhea. The chosen population consists of 190 hospitalized patients taking antibiotics. Preselected and randomized patients will take probiotics once daily until 1 week after the course of antibiotic is over or a placebo with 0 CFU. The primary outcome is to detect the occurrence of an antibiotic-associated diarrhea. The secondary outcome is to assess the presence of Clostridium difficile toxins in stool culture. Condition or disease (...) a placebo regimen. Primary Purpose: Prevention Official Title: Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea; A Randomized Double Blind Placebo Controlled Trial. Estimated Study Start Date : September 1, 2018 Estimated Primary Completion Date : December 31, 2018 Estimated Study Completion Date : March 31, 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment

2018 Clinical Trials

76. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (Abstract)

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety (...) and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC.This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end

2020 EvidenceUpdates

77. Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial

on admission and during follow up measured by patient interview Combined safety endpoints in regard to side effects from nutritional therapy [ Time Frame: measured at day 30 ] Number of participants with side effects from nutritional therapy including (a) adverse gastrointestinal effects (diarrhea, nausea, vomiting, abdominal pain) assessed by patient interview (yes/no) b) Complications due to tube feeding or center catheter for parenteral nutrition assessed by medical chart review (c) Refeeding syndrome (...) Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2015 Clinical Trials

78. Massage therapy for the treatment of children's diarrhea: a systematic review and meta-analysis

Massage therapy for the treatment of children's diarrhea: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used

2017 PROSPERO

79. Systematic review of the effectiveness of zinc as an adjunct therapy in diarrhoea treatment in children 0-5 years

Systematic review of the effectiveness of zinc as an adjunct therapy in diarrhoea treatment in children 0-5 years Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence (...) by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about

2017 PROSPERO

80. Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25

Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25 1 Translation of addendum A17-53 Etelcalcetid (sekundärer Hyperparathyreoidismus) – Addendum zum Auftrag A17-25 (Version 1.0; Status: 27 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 27 October 2017 1.0 Commission: A17-53 Version: Status: IQWiG Reports (...) – Commission No. A17-53 Etelcalcetide (secondary hyperparathyroidism – Addendum to Commission A17-25 1 Addendum A17-53 Version 1.0 Etelcalcetide – Addendum to Commission A17-25 27 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Etelcalcetide (secondary hyperparathyroidism – Addendum to Commission A17-25 Commissioning agency: Federal Joint Committee Commission awarded on: 9 October 2017

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>